At the news
? NEUTRALIMPACT 3/10 8-K filed Apr 13, 2026 at 08:30 ET
CG Oncology appointed Jim DeTore as Chief Financial Officer, effective April 13, 2026. The appointment follows his interim role since November 2025 and includes a formal employment agreement with a $520,000 annual base salary and $5 million in initial equity awards.
- Jim DeTore was formally appointed Chief Financial Officer effective April 13, 2026
- DeTore had been serving as Interim Principal Financial and Accounting Officer since November 2025
- He receives a $520,000 annual base salary and is eligible for a 45% target annual bonus
- He received an initial stock option grant valued at $4 million and a performance stock unit award valued at $1 million
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access